

(43) International Publication Date  
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number  
WO 2005/058959 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/775, A61K 38/10, A61P 31/12

(21) International Application Number: PCT/GB2004/005360

(22) International Filing Date: 17 December 2004 (17.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0329254.7 17 December 2003 (17.12.2003) GB

(71) Applicant (for all designated States except US): THE UNIVERSITY OF MANCHESTER [GB/GB]; Oxford Road, Manchester M13 9PL (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): DOBSON, Curtis [GB/GB]; Faculty of Life Sciences, Moffat Building, University of Manchester, P.O. Box 88, Manchester M60 1QD (GB).

(74) Agent: BANFORD, Paul, Clifford; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only


## Published:

— with international search report

[Continued on next page]

(54) Title: TREATMENT OF VIRAL INFECTIONS

## Reduction in HSV1 infectivity after treatment with various concentrations of apoEderived peptides



(57) Abstract: The present invention concerns polypeptides derived from a tandem repeat of apoE<sub>141-149</sub> and their uses as medicaments. The peptides may comprise the tandem repeat, and truncations thereof, for which at least one Leucine (L) is replaced by an amino acid with a side chain comprising at least 4 carbon atoms and at least one Nitrogen atom. Such peptides are useful for preventing or treating viral infections.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(88) Date of publication of the international search report:

15 December 2005